Clinical Trial Update: Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV [Phase 2]

View source ↗

Summary

The document reports the completion of a Phase 2 trial evaluating erlotinib as first-line therapy for non-small cell lung cancer in stage IIIB/IV.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Hellenic Oncology Research Group | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED